Radiolabelling and cellular binding studies of metformin and indomethacin loaded dual niosome formulations on human colorectal adenocarcinoma cell line

OpenAlex İngilizce

In the current work, film hydration was used for producing indomethacin- and metformin-loaded dual niosomes with a particle size of < 150 nm, a polydispersity index of < 0.5, and a charge of between -30 and -50 mV. [99mTc]Tc was used as a radiolabel for all niosome formulations using stannous chloride as reducing agents. Radioactive thin-layer chromatography (RTLC) was used to evaluate the niosome formulations' radiochemical purity (RP) and stability. Next, the cellular binding of reduced/hydrolyzed (R/H)-[99mTc]NaTcO4 and [99mTc]Tc-labelled niosome formulations was evaluated in human colorectal adenocarcinoma cells. Radiolabelling all niosomes with [99mTc]Tc for 15 min at 500 μg.mL–1 stannous chloride resulted in successful radiolabelling, with an observed RP of over 95%. The cell binding percentages of [99mTc]Tc-labelled niosome formulations in cancer cells were higher than those of R/H- [99mTc]NaTcO4. Finally, the recently developed dual-niosome formulations of metformin and indomethacin labelled with [99mTc]Tc may prove effective for nuclear medicine imaging.